Proteome Sciences Inks Deal with Eisai for First Commercial Use of Alzheimer's Biomarker Panel

The agreement calls for Proteome Sciences to quantify plasma levels of the nine proteins in its AD-TMT-SRM panel, which uses multiple-reaction-monitoring mass spectrometry and the company's Tandem Mass Tagging technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.